Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9602250 | 0.87 | TSHR (0.36) | TSHRKMT2AMEN1CA12CA14 | |
| SCHEMBL7164146 | 0.78 | TSHR (0.36) | TSHRKMT2AMEN1 | |
| SCHEMBL2677950 | 0.76 | ALDH1A1 (0.39) | TSHRKMT2AMEN1LMNACA12 | |
| SCHEMBL3761727 | 0.76 | NAAA (0.44) | TSHRLMNACA12ALDH1A1 | |
| SCHEMBL7042625 | 0.75 | NAAA (0.47) | TSHRLMNACA12ALDH1A1 | |
| SCHEMBL12532804 | 0.73 | TSHR (0.46) | TSHRKMT2AMEN1LMNACA12 | |
| SCHEMBL12390082 | 0.70 | TSHR (0.52) | TSHRKMT2AMEN1LMNACA12 | |
| SCHEMBL3453928 | 0.69 | TSHR (0.57) | TSHRKMT2AMEN1LMNACA12 | |
| SCHEMBL5872657 | 0.69 | TSHR (0.34) | TSHRLMNA | |
| SCHEMBL1070843 | 0.68 | HDAC1 (0.34) | TSHRLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043010-A1 | Quinazoline derivatives | ASTRAZENECA UK LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
| US-7105032-B2 | Agents used for dyeing keratinous fibers | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (HENKEL KGAA) (DE) | 2006-09-12 | — | — | US | disclosed |
| US-20050144740-A1 | Agents used for dyeing keratinous fibers | HENKEL AG & CO. KGAA (DE) | 2005-07-07 | — | — | US | disclosed |
| US-5002942-A | Calcium channel blockers for cardiovascular disorders | SANKYO COMPANY, LIMITED (JP) | 1991-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043010-A1 | Quinazoline derivatives | ERBB2, ABL1, EGFR | TSHR 1244/4885KMT2A 2314/4885MEN1 1655/4885 |
| US-20050144740-A1 | Agents used for dyeing keratinous fibers | KRT18, TUBB3, DSG1 | TSHR 4859/4885KMT2A 1260/4885MEN1 4420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.